A new study improves the chances of finding the right drug to kill individual cancers in children by incorporating high-throughput drug screening into precision medicine. The approach reveals additional drug sensitivities and predicts clinical response, leading to better treatment options.
Researchers at Children's Cancer Institute Australia have developed a targeted drug delivery system that can selectively target leukaemia cells, reducing toxicity and improving treatment success. The approach has shown promising results in laboratory tests and living models of the disease, with potential applications for other types of...
A new DNA-based test using whole genome sequencing can identify tumour-specific markers to measure cancer levels in children's bodies. This technology has the potential to detect minimal residual disease and change treatment outcomes.
The Zero Childhood Cancer Program, a precision medicine program, has received a $600k donation from The Lott to enhance research capabilities and provide personalized treatment plans to children with high-risk cancer. Over 70% of enrolled patients have shown a response, with some tumours stabilized or shrunk.
Australian scientists have discovered a new and effective way to treat high-risk blood cancer in children. A combination of ruxolitinib with commonly used anticancer drugs showed enhanced treatment efficacy in two out of three patient-derived xenograft models, achieving long-term suppression of leukaemia growth.
Researchers found a highly effective treatment for high-risk neuroblastoma and other forms of aggressive childhood cancer. The combination of CBL0137 and panobinostat resulted in remarkable growth suppression and an immune response that targeted cancer cells.
Australian researchers have discovered a new therapeutic approach for treating Diffuse Intrinsic Pontine Glioma (DIPG), a currently incurable brain cancer in children. Using the anti-cancer compound CBL0137, which targets the key genetic driver of DIPG, has shown promising results in both laboratory tests and animal models.
Australian researchers have made a world-first discovery in targeting an aggressive childhood cancer, neuroblastoma. They found that the cellular protein ALYREF plays a crucial role in accelerating MYCN-driven cancer growth in neuroblastoma cells.
Researchers have identified a potential revolutionary drug combination that is 'spectacularly effective' in eradicating DIPG cancer cells. The treatment, a combination of difluoromethylornithine (DFMO) and AMXT 1501, was found to be highly effective in animal studies and pre-clinical testing.
The Zero Childhood Cancer Personalised Medicine Program has identified the molecular basis of childhood cancers in over 90% of cases and found at least one new potential treatment option in 70% of children. Early results show that tumours shrank or stopped growing in 30% and 40% of cases, respectively.
Researchers discovered that removing copper from blood can destroy some deadly cancers resistant to immunotherapy. High levels of copper in cancer cells increase expression of PD-L1, a protein that hides cancer cells from the immune system.
Children's Cancer Institute researchers have discovered a new approach to treating acute myeloid leukaemia (AML) by targeting leukemia stem cells. The therapy disrupts the ability of these cells to self-renew, markedly reducing leukaemia amounts and preventing new cells from growing.
Researchers have identified a promising drug candidate OT-82 that demonstrates remarkable efficacy in preclinical models. It targets the NAMPT enzyme responsible for NAD production, showing potential as a novel treatment option for refractory blood cancers.
A new approach to treating MLL-rearranged leukaemia (MLL-r leukaemias) has shown promising results, with a small molecule inhibitor called VTP50469 producing a 'dramatic response' in specially-bred mice. The therapy is designed to target molecules critical for the survival and growth of cancer cells.
A new study published in British Journal of Cancer has identified the protein stathmin as a crucial player in the spread of neuroblastoma. Stathmin helps regulate PTPN14 expression, affecting migration and invasion of neuroblastoma cells.
Researchers have identified a new target molecule for treating childhood cancer neuroblastoma, which may lead to more effective treatments. The study found that high levels of a long non-coding RNA called 'lncNB1' are associated with poor prognosis, and its inhibition can cause cancer cells to die.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Australian researchers have identified a gene called JMJD6 that plays a key role in the most aggressive form of neuroblastoma. The discovery opens up new possibilities for targeted drug therapy, with promising results shown in animal models.
Researchers have found a safer way to treat T-ALL, a type of leukemia mainly affecting children. The breakthrough involves targeting specific versions of the gamma-secretase complex, which stops cancer growth without causing toxicity.
Researchers identified a crucial link between polyamines and the MYCN oncogene, revealing a new therapeutic approach to disrupt cancer cell growth. A combination therapy of DFMO and AMXT-1501 showed significant increase in survival in mice with established neuroblastoma tumours.
Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or 'microdeletions'. The study tested 475 patients and found that the new score is more accurate than the current approach, allowing doctors to better predict relapse risk.
Australian scientists identified a critical molecular feedback loop in neuroblastoma that accelerates cancer development. Experimental drug CBL0137 has the potential to interrupt this loop and halt tumour progression, showing promising results in laboratory models.
Children's Cancer Institute Australia has been awarded close to $2 million to test new drugs in preclinical models of acute lymphoblastic leukaemia (ALL) under the Pediatric Preclinical Testing Consortium (PPTC). The PPTC will facilitate the acceleration of effective drugs into clinical trials.
A new Australian study has found a promising drug, PR-104, effective against aggressive T-ALL in laboratory models. The research team is now exploring the molecular biology behind AKR1C3, an enzyme that activates the drug.